Skip to main content
Clinical Trials/NCT01318382
NCT01318382
Completed
Phase 4

Residual Curarization and Its Incidence at Tracheal Extubation

Merck Sharp & Dohme LLC0 sites302 target enrollmentJune 2011

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Observation of Neuromuscular Block
Sponsor
Merck Sharp & Dohme LLC
Enrollment
302
Primary Endpoint
Percentage of Participants With Residual Neuromuscular Blockade (NMB)(Train of Four [TOF] Ratio <0.9) at Time of Tracheal Extubation
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This study will assess the residual neuromuscular blockade (NMB) Train-Of-Four (TOF) ratios at tracheal extubation when anesthesiologists have determined that full recovery of neuromuscular function has occurred using standard clinical criteria for participants whose non-depolarizing-induced NMB is either not reversed or reversed with an acetylcholinesterase inhibitor administered as per standard routine care.

Detailed Description

This is an observational cohort study with a device intervention to determine in which cohort the subject is falling.

Registry
clinicaltrials.gov
Start Date
June 2011
End Date
May 2012
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Participant must be American Society of Anesthesia (ASA) class 1-
  • Participant must be scheduled for elective open or laparoscopic abdominal surgery that is anticipated to last less than 4 hours.
  • Administration of general anesthesia and ≥ 1 dose of non-depolarizing neuromuscular blockers for endotracheal intubation or maintenance of neuromuscular blockade.
  • Extubation must occur in the operating room (OR).

Exclusion Criteria

  • Surgery re-admission on the same hospital admission.
  • Pre-established need for or expected to require post-operative mechanical ventilation.
  • Conditions, surgical procedures or position that may interfere with the TOF-Watch SX® operation, calibration or accuracy.
  • Administration of sugammadex (Bridion®) for reversal of neuromuscular blockade.
  • Participation in any other clinical trial.
  • Member or a family member of the personnel of the investigational or Sponsor staff directly involved with this trial.
  • Anesthesiologist use of objective neuromuscular monitoring during surgery (e.g. mechanomyography, electromyography or related method).

Outcomes

Primary Outcomes

Percentage of Participants With Residual Neuromuscular Blockade (NMB)(Train of Four [TOF] Ratio <0.9) at Time of Tracheal Extubation

Time Frame: Up to 1 minute prior to tracheal extubation

Neuromuscular functioning was monitored at time of tracheal extubation by applying three TOF electrical stimulations to the ulnar nerve and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (height) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB, with a higher ratio indicating greater recovery from NMB. A T4/T1 Ratio of \<0.9 is indicative of residual NMB.

Secondary Outcomes

  • Percentage of Participants With Residual NMB (TOF Ratio <0.9) Upon Arrival to the Post-anesthesia Care Unit (PACU)(Up to 2 minutes prior to PACU arrival)
  • Percentage of Participants With Residual NMB at Various TOF Ratios (<0.6, ≥0.6 to <0.7, ≥0.7 to <0.8, ≥0.8 to <0.9) at Tracheal Extubation(Up to 1 minute prior to tracheal extubation)
  • Percentage of Participants With Residual NMB at Various TOF Ratios (<0.6, ≥ 0.6 to <0.7, ≥ 0.7 to <0.8, ≥0.8 to <0.9) Upon Arrival to the PACU(Up to 2 minutes prior to PACU arrival)

Similar Trials